孟鲁司特和鼻用莫美他松复方制剂对儿童腺样体肥大的影响

Q3 Medicine
Mohsen Jafari, Bahar Pourroshani, Kambiz Eftekhari, Armen Malekiantaghi, Parisa Ashournia, Alireza Shafiei
{"title":"孟鲁司特和鼻用莫美他松复方制剂对儿童腺样体肥大的影响","authors":"Mohsen Jafari, Bahar Pourroshani, Kambiz Eftekhari, Armen Malekiantaghi, Parisa Ashournia, Alireza Shafiei","doi":"10.22038/IJORL.2024.73906.3490","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Adenoid hypertrophy is a common childhood disease; its standard treatment is adenoidectomy. The desire for medical management is increasing due to fewer complications and more convenience. The present study investigated the effect of adding oral montelukast to mometasone nasal spray in treating adenoid hypertrophy.</p><p><strong>Materials and methods: </strong>This was a randomized, double-blind, placebo-controlled study conducted at a referral teaching hospital (Tehran, Iran) from September 2020 to September 2021. Children aged 2 to 14 years with clinical and radiological findings of adenoid hypertrophy were enrolled. Patients were randomly divided into two groups: mometasone nasal spray with oral montelukast (case group) or mometasone with placebo (control group). Then, the clinical scores were compared before and two months after the intervention.</p><p><strong>Results: </strong>Ninety-six patients completed the study [62.5% male (n=60)]. Of these, 51 were in the case and 45 in the control group. The clinical score in each group decreased significantly after the intervention (P<0.001), but the decrease in clinical score in the case group was not significantly different from the control (p=0.576).</p><p><strong>Conclusion: </strong>The results showed that the combination therapy with mometasone and montelukast has the same efficacy as mometasone and placebo in treating adenoid hypertrophy. Adding montelukast to mometasone has no additional effect.</p>","PeriodicalId":14607,"journal":{"name":"Iranian Journal of Otorhinolaryngology","volume":"36 2","pages":"391-397"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10925965/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of Combination Montelukast and Nasal Mometasone on Childhood Adenoid Hypertrophy.\",\"authors\":\"Mohsen Jafari, Bahar Pourroshani, Kambiz Eftekhari, Armen Malekiantaghi, Parisa Ashournia, Alireza Shafiei\",\"doi\":\"10.22038/IJORL.2024.73906.3490\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Adenoid hypertrophy is a common childhood disease; its standard treatment is adenoidectomy. The desire for medical management is increasing due to fewer complications and more convenience. The present study investigated the effect of adding oral montelukast to mometasone nasal spray in treating adenoid hypertrophy.</p><p><strong>Materials and methods: </strong>This was a randomized, double-blind, placebo-controlled study conducted at a referral teaching hospital (Tehran, Iran) from September 2020 to September 2021. Children aged 2 to 14 years with clinical and radiological findings of adenoid hypertrophy were enrolled. Patients were randomly divided into two groups: mometasone nasal spray with oral montelukast (case group) or mometasone with placebo (control group). Then, the clinical scores were compared before and two months after the intervention.</p><p><strong>Results: </strong>Ninety-six patients completed the study [62.5% male (n=60)]. Of these, 51 were in the case and 45 in the control group. The clinical score in each group decreased significantly after the intervention (P<0.001), but the decrease in clinical score in the case group was not significantly different from the control (p=0.576).</p><p><strong>Conclusion: </strong>The results showed that the combination therapy with mometasone and montelukast has the same efficacy as mometasone and placebo in treating adenoid hypertrophy. Adding montelukast to mometasone has no additional effect.</p>\",\"PeriodicalId\":14607,\"journal\":{\"name\":\"Iranian Journal of Otorhinolaryngology\",\"volume\":\"36 2\",\"pages\":\"391-397\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10925965/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Otorhinolaryngology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22038/IJORL.2024.73906.3490\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Otorhinolaryngology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/IJORL.2024.73906.3490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

简介腺样体肥大是一种常见的儿童疾病,其标准治疗方法是腺样体切除术。由于并发症更少、更方便,人们对药物治疗的渴望与日俱增。本研究探讨了在莫米松鼻腔喷雾剂中添加口服孟鲁司特治疗腺样体肥大的效果:这是一项随机、双盲、安慰剂对照研究,于 2020 年 9 月至 2021 年 9 月在一家转诊教学医院(伊朗德黑兰)进行。研究对象为临床和放射学检查发现腺样体肥大的 2 至 14 岁儿童。患者被随机分为两组:莫美他松鼻喷雾剂与口服孟鲁司特(病例组)或莫美他松与安慰剂(对照组)。然后,比较干预前和干预后两个月的临床评分:96名患者完成了研究[62.5%为男性(n=60)]。其中,病例组 51 人,对照组 45 人。干预后,各组患者的临床评分均有明显下降(PConclusion:结果显示,在治疗腺样体肥大方面,莫美他松和孟鲁司特的联合疗法与莫美他松和安慰剂的疗效相同。在莫美他松基础上添加孟鲁司特没有额外效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of Combination Montelukast and Nasal Mometasone on Childhood Adenoid Hypertrophy.

Introduction: Adenoid hypertrophy is a common childhood disease; its standard treatment is adenoidectomy. The desire for medical management is increasing due to fewer complications and more convenience. The present study investigated the effect of adding oral montelukast to mometasone nasal spray in treating adenoid hypertrophy.

Materials and methods: This was a randomized, double-blind, placebo-controlled study conducted at a referral teaching hospital (Tehran, Iran) from September 2020 to September 2021. Children aged 2 to 14 years with clinical and radiological findings of adenoid hypertrophy were enrolled. Patients were randomly divided into two groups: mometasone nasal spray with oral montelukast (case group) or mometasone with placebo (control group). Then, the clinical scores were compared before and two months after the intervention.

Results: Ninety-six patients completed the study [62.5% male (n=60)]. Of these, 51 were in the case and 45 in the control group. The clinical score in each group decreased significantly after the intervention (P<0.001), but the decrease in clinical score in the case group was not significantly different from the control (p=0.576).

Conclusion: The results showed that the combination therapy with mometasone and montelukast has the same efficacy as mometasone and placebo in treating adenoid hypertrophy. Adding montelukast to mometasone has no additional effect.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Iranian Journal of Otorhinolaryngology
Iranian Journal of Otorhinolaryngology Medicine-Otorhinolaryngology
CiteScore
1.30
自引率
0.00%
发文量
72
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信